500 myeloma patients to be tracked in Real-World immunotherapy study

NCT ID NCT07296627

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 500 Chinese patients newly diagnosed with multiple myeloma who are receiving immunotherapy as their first treatment. Researchers will collect data on which treatments are used and how well they work over one year, with longer follow-up for survival. The goal is to improve personalized treatment decisions in real-world clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could provide real-world evidence to guide better treatment decisions for multiple myeloma patients in China.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, China